PR Newswire
VADUZ, Liechtenstein, Aug. 23, 2022
VADUZ, Liechtenstein, Aug. 23, 2022 /PRNewswire/ --
Executing on RefluxStop™ Commercialisation Strategy
Significant events in the second quarter of 2022
Significant events after the end of the period
Second quarter financial summary
First six months financial summary
Implantica will hold a telephone conference on August 23 at 15:00 CEST.
The presentation will be in English via an audiocast with teleconference:
Conference call dial-in:
Webcast:
https://tv.streamfabriken.com/implantica-q2-2022
Speakers:
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on August 23, 2022 at 08:00 a.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-publishes-interim-report-q2-2022,c3618050
The following files are available for download:
Q2 2022_ENG_Full_Final_v2 | |
https://mb.cision.com/Public/19732/3618050/a78cf84edac8e64a.pdf | Implantica publishes Interim Report Q2 2022 |
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.